Mitigating overdiagnosis and overtreatment in breast cancer: What is the role of the pathologist?

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 11, 2014, Pages 1428-1431

  Calhoun, Benjamin C ^a   Livasy, Chad A ^a,b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE COURSE; FEMALE; HUMAN; HYPERPLASIA; MAMMARY GLAND; MASS SCREENING; NOMENCLATURE; PATHOLOGY; PHYSICIAN ATTITUDE; PRECANCER; RISK FACTOR; TUMOR INVASION;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERPLASIA; MAMMARY GLANDS, HUMAN; MASS SCREENING; NEOPLASM INVASIVENESS; PATHOLOGY, CLINICAL; PHYSICIAN'S ROLE; PRECANCEROUS CONDITIONS; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 84916623828     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0763-ED     Document Type: Editorial

References (30)

1. O'Donoghue C, Esserman L. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer. 2013;108(11):2200-2201.
2. Esserman LJ, Thompson IM Jr, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013;310(8):797-798.
3. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605-613.
4. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685-1692.
5. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
8. Webb ML, Cady B, Michaelson JS, et al. A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened [published online ahead of print September 9, 2013]. Cancer. doi: 10.1002/cncr.28199.
9. Eklund M, Esserman LJ. Screening: biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol. 2013;10(12):673-675.
10. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26(5):729-735.
11. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721-728.
12. Nekhlyudov L, Habel LA, Achacoso N, et al. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. J Natl Cancer Inst. 2012;104(8):614-621.
13. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013;173(19):1830-1831.
14. Punglia RS, Schnitt SJ, Weeks JC. Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate? J Natl Cancer Inst. 2013;105(20):1527-1533.
15. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319-5324.
16. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701-710.
17. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013 [published online ahead of print October 12, 2013]. CA Cancer J Clin. 2014;64(1):52-62. doi: 10.3322/caac.21203.
18. Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer. 2007;109(2):180-187.
19. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6(5):297-301.
20. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229-237.
21. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast: a long-term follow-up study. Cancer. 1985;55(11):2698-2708.
22. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer. 1990;66(6)(suppl):1326-1335.
23. Foster MC, Helvie MA, Gregory NE, Rebner M, Nees AV, Paramagul C. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? Radiology. 2004;231(3):813-819.
24. Ciatto S, Houssami N, Ambrogetti D, et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. Breast Cancer Res Treat. 2007;101(3):291-297.
25. Desouki MM, Li Z, Hameed O, Fadare O, Zhao C. Incidental atypical proliferative lesions in reduction mammoplasty specimens: analysis of 2498 cases from 2 tertiary women's health centers. Hum Pathol. 2013;44(9):1877-1881.
26. Liberman L. Clinical management issues in percutaneous core breast biopsy. Rad Clin N Am. 2000;38(4):791-807.
27. Ceugnart L, Doualliez V, Chauvet MP, et al. Pure flat epithelial atypia: is there a place for routine surgery? Diagn Interv Imaging. 2013;94(9):861-869.
28. Georgian-Smith D, Lawton TJ. Variations in physician recommendations for surgery after diagnosis of a high-risk lesion on breast core needle biopsy. AJR Am J Roentgenol. 2012;198(2):256-263.
29. Boulos FI, Dupont WD, Simpson JF, et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer. 2008;113(9):2415-2421.
30. Boulos FI, Dupont WD, Schuyler PA, et al. Clinicopathologic characteristics of carcinomas that develop after a biopsy containing columnar cell lesions: evidence against a precursor role. Cancer. 2012;118(9):2372-2377.